Correlative Factors of PD-1/PD-L1 Inhibitors-based Immunotherapy Responses in Non-small Cell Lung Cancer

Caiwei Wang

doi:10.62051/mgznvq03

Authors

Caiwei Wang

DOI:

https://doi.org/10.62051/mgznvq03

Keywords:

NSCLC; PD-1/PD-L1; immunotherapy.

Abstract

The use of immunotherapy as a treatment modality in the field of cancer has garnered significant attention since its discovery. Among these, studies have demonstrated the substantial benefits of using programmed death 1 (PD1)/programmed death ligand 1 (PD-L1) inhibitors in the treatment of non-small cell lung cancer (NSCLC). However, as research continues, there are differing advantages and disadvantages to this treatment for NSCLC. Adverse effects related to the immune system and high costs are also faced by patients undergoing this therapy. As a result, the creation of biomarkers is crucial for the immunotherapy of cancer. Numerous studies have examined immunotherapy's side effects in non-small cell lung cancer. Therefore, on the basis of previous studies, this article reviews the factors related to the involvement of PD-1/PD-L1 inhibitors in the immunotherapy response of NSCLC, in order to find candidate drugs and more effective biological treatments for PD-1/PD-L1 inhibitors. Markers provide direction and theoretical basis.

Downloads

Download data is not yet available.

References

Zhang Qinchang, Wang Buhai. Research progress of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer. Chinese Folk Medicine, 2017, 29 (12): 44 - 46.

Peng Zhanxian, Yang Ning. Research progress of PD-1/PD-L1 inhibitors in non-small cell lung cancer. Journal of Clinical Pulmonology, 2019, 24 (6): 1147 - 1149.

Li-Na He, Sha Fu, Xuanye Zhang, et al. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy, Lung Cancer, 2021, Volume 158, pp 1-8.

Niki Gavrielatou, Yuting Liu, Ioannis Vathiotis, Jon Zugazagoitia, Thazin Nwe Aung, Saba Shafi, Aileen Fernandez, Kurt Schalper, Amanda Psyrri, David L. Rimm; Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer. Clin Cancer Res 15 January 2022, 28 (2): 360 – 367.

Wang Xiaoyan, Wu Bingchen, Yan Zhengqing, et al. Association of PTPRD/PTPRT Mutation with Better Clinical Outcomes in NSCLC Patients Treated with Immune Checkpoint Blockades, Frontiers in Oncology, 2021, Volume 11.

Francisco, L.M., Sage, P.T. and Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews, 2010, 236: 219 - 242.

Bai J, Gao Z, Li X, et al. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget. 2017 Nov 25; 8 (66): 110693 - 110707.

Guerreiro IM, Barros-Silva D, Lopes P, et al. RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 2020; 9 (4): 1000.

Hironori Yoshida, Takashi Nomizo, Hiroaki Ozasa, et al. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade, European J Cancer, Volume 144, 2021, Pages 317 - 325.

Wang Xiaoyan, Wu Bingchen, Yan Zhengqing, et al. Association of PTPRD/PTPRT Mutation with Better Clinical Outcomes in NSCLC Patients Treated with Immune Checkpoint Blockades, Frontiers in Oncology, 2021, Volume 11.

Raza Afsheen, Mohsen Reyad, Kanbour Aladdin, et al. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression, Frontiers in Immunology, 2023, Volume 14.

Kang, D.H., Chung, C., Sun, P. et al. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. Cancer Immunol Immunother 2022, 71, 579 – 588.

Huang, Ying MM; Shen, Aizong MD*. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis. Medicine 2023, 99 (34): p e21718.